Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Sepax-tech

Explore full profile

Better Surface Chemistry for Better Separation

Newark, United StatesFounded 2002Biotech & Life Sciences
Valuation $250–500M Last recorded · 2021
Headcount <100 Current team size
Total funding $100–500M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Sepax-tech and the history behind them.

About Sepax-tech

Sepax Technologies, Inc. is a specialized company that operates in the biotechnology market, providing high-tech solutions for the separation and analysis of biomolecules. Their products are primarily used in the pharmaceutical and biotech industries, serving clients who require precise and reliable methods for analyzing complex biological substances.

The company's main offerings include Proteomix® HIC Butyl columns and Monomix™ MC SEC resins. The Proteomix® HIC Butyl columns are used for high-resolution hydrophobic interaction separation of biomolecules, such as monoclonal antibodies (mAb), Antibody Drug Conjugates (ADCs), and their fragments. Simply put, these columns help to separate complex biological substances based on their hydrophobicity, or their tendency to repel water.

The Monomix™ MC SEC resins, on the other hand, are used for size exclusion chromatography (SEC), a method used to separate biomolecules based on their size. These resins are particularly stable and versatile, with a broad pH tolerance range and compatibility with many commonly used solvents and buffers.

Sepax Technologies also offers a full chromatographic separation solution for ADCs, which includes a range of products for the analysis of ADCs aggregate, monomer, fragment, and free drug. This comprehensive solution allows for detailed analysis of ADCs, which are complex molecules used in targeted cancer therapies.

The company's business model is based on selling these high-tech products and solutions to clients in the biotech and pharmaceutical industries. They also offer technical support to their clients, ensuring that their products are used effectively and efficiently.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2002
Headquarters
Newark, United States
Employees
87
Open positions
1
Dealroom signal
38.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Tech for Biotech and Pharma, Biotech and Pharma, Hard Tech, Resin, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES DOther financing Nov 2021 $69M $275M CITIC PE · Sinovac Biotech · Gan & Lee Pharmaceutical · Sherpa Venture Partners ↗
SERIES COther financing Mar 2021 $28M $110M China Life Healthcare Fund · Fosun Capital ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Sepax-tech website traffic

Latest recorded traffic for Sepax-tech is 5.3K monthly website visits, up 29.3% over the last three months. Sepax-tech's team grew 0% over the past year.

Latest monthly visits5.3K 3-month web change+29.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom
1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
PhaseVUses advanced algorithms to optimize clinical trials, improving success rates, efficiency, and uncovering hidden signals in the data Tel Aviv-Yafo, Israel Operational 71 $65M $200M
Comera Life SciencesEnhancing therapeutic protein formulations for better patient experience and extended product lifecycle Woburn, United States Operational
Wheeler BioBy bringing together biologics drug innovators, discovery CROs, and CDMOs accelerating the translation of therapeutic innovation to clinical impact Oklahoma City, United States Operational
Tesis LabsA unique integrated medical platform that is revolutionizing targeted genetic sequencing Phoenix, United States Operational
Celeris TherapeuticsPredicting biomolecular interactions and designing drugs for incurable diseases Graz, Austria Operational
Rubix strategiesA research and development company focusing on the gaps of product development toward effective patient outcomes through real-world evidence design and creating digital platforms for increasing patient diversity in Phase I/II clinical trials Lawrence, United States Operational
ExogeneBiotechnology company accelerating target and TCR discovery for cancer cell therapies using AI-enabled TCR-antigen screening Oxford, United Kingdom Operational
EleusisLeusis is a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, guided by science and enabled by drug discovery, clinical development and care delivery design London, United Kingdom Acquired
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • Comway Capital
  • Huatai Zijin Investment
  • Suzhou Dunhang Investment Management

Series B and later8 investors entered at this stage

  • China Life Healthcare Fund
  • Fosun Capital
  • CITIC PE
  • Sinovac Biotech
  • Gan & Lee Pharmaceutical
  • Sherpa Venture Partners
  • GL Ventures
  • Sinopharm Capital
Employees 87 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States80.8%
🇨🇳 China17.3%
🇬🇧 United Kingdom1.9%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Sepax-tech on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Sepax-tech’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.